Multiple Myeloma Clinical Trial
Descartes-11 in Multiple Myeloma
Summary
This Phase I/2 study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Active multiple myeloma that is refractory after at least 2 prior lines of therapy;
measurable disease;
adequate vital organ function; and
no active infection.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There are 2 Locations for this study
See Locations Near You
Center for Cancer and Blood Disorders
Bethesda Maryland, 20817, United States
Bethesda Maryland, 20817, United States
Medical College of Wisconsin
Madison Wisconsin, 53226, United States
Madison Wisconsin, 53226, United States
How clear is this clinincal trial information?